Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III acquired 6,000 shares of the business’s stock in a transaction dated Wednesday, June 28th. The stock was purchased at an average price of $19.94 per share, for a total transaction of $119,640.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Xencor, Inc. (XNCR) traded down 0.33% during midday trading on Friday, hitting $21.11. The company had a trading volume of 259,847 shares. Xencor, Inc. has a one year low of $17.65 and a one year high of $29.38. The firm has a market cap of $985.90 million, a price-to-earnings ratio of 59.80 and a beta of 2.13. The company’s 50 day moving average is $21.44 and its 200 day moving average is $23.56.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.06. Xencor had a return on equity of 5.98% and a net margin of 18.19%. The company had revenue of $4.34 million during the quarter, compared to analyst estimates of $8.15 million. Equities analysts forecast that Xencor, Inc. will post ($1.21) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Xencor, Inc. (XNCR) Major Shareholder John S. Stafford III Acquires 6,000 Shares” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/06/30/xencor-inc-xncr-major-shareholder-john-s-stafford-iii-acquires-6000-shares.html.

Several institutional investors have recently bought and sold shares of XNCR. Two Sigma Investments LP boosted its position in Xencor by 50.3% in the fourth quarter. Two Sigma Investments LP now owns 49,404 shares of the biopharmaceutical company’s stock valued at $1,300,000 after buying an additional 16,523 shares in the last quarter. Norges Bank acquired a new position in Xencor during the fourth quarter valued at $15,601,000. Metropolitan Life Insurance Co. NY boosted its position in Xencor by 5.2% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 24,914 shares of the biopharmaceutical company’s stock valued at $656,000 after buying an additional 1,227 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Xencor during the fourth quarter valued at $2,213,000. Finally, Creative Planning boosted its position in Xencor by 2.7% in the first quarter. Creative Planning now owns 38,400 shares of the biopharmaceutical company’s stock valued at $919,000 after buying an additional 1,000 shares in the last quarter. 75.00% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on XNCR shares. Zacks Investment Research downgraded Xencor from a “buy” rating to a “hold” rating in a report on Saturday, April 29th. Wedbush restated an “outperform” rating and issued a $29.00 price objective on shares of Xencor in a report on Wednesday, May 10th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $28.67.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.